News

Pfizer licenses 3SBio cancer drug for $1.25B upfront
Pfizer (NYSE:PFE) has signed an exclusive global licensing deal with China’s 3SBio for the development of its cancer drug ...
Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake
U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion ...